Attached files
file | filename |
---|---|
EX-99.1 - ASSEMBLY BIOSCIENCES, INC. | v209735_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 1,
2011
VENTRUS
BIOSCIENCES, INC.
|
||
(Exact
name of registrant as specified in its charter)
|
Delaware
|
20-8729264
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer ID Number)
|
787
7th
Avenue, 48th
Floor, New York, New
York 10019
|
(Address
of principal executive
offices) (Zip
Code)
|
Registrant’s
telephone number, including area code
|
(212)
554-4300
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01. Other Events.
On
February 1, 2011, Ventrus Biosciences, Inc., issued a press release announcing
the completion of its clinical development staffing. A copy of the
press release is attached hereto as Exhibit 99.1 and is incorporated herein
in its entirety by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
|
Exhibits
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
release dated February 1, 2011.
|
2
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
VENTRUS
BIOSCIENCES, INC.
|
|||
Date: February
1, 2011
|
By:
|
/s/ David J. Barrett | |
David J. Barrett, Chief Financial Officer | |||
3